Top Cannabis News Stories for May 15, 2026
Top Cannabis News Stories for May 15, 2026 — tailored for The Stoner Review audience.
1. Congress Fractures on Federal Rescheduling
The House Appropriations Committee advanced a spending bill with a rider blocking federal funds for further cannabis rescheduling (32-28 vote), directly challenging the Trump administration’s move of state-licensed medical marijuana to Schedule III. At the same time, the full House passed a bipartisan amendment allowing veterans to discuss medical cannabis with VA doctors. This push-pull highlights ongoing federal tension.
Why it matters: Potential roadblocks to broader reform, 280E tax relief, and research expansion — but also incremental wins for medical access.
2. Historic Bankruptcy Protection for Cannabis Company
A Delaware court granted federal bankruptcy protection to a cannabis business for the first time, offering a lifeline amid financial pressures in the regulated market. This could open doors for more operators facing challenges post-rescheduling.
Relevance: Signals growing legitimacy and new financial tools for the industry — critical for growers and businesses navigating volatility.
3. DEA Registration Portal Live for Medical Cannabis Businesses
Operators are racing to file for DEA registration under the new Schedule III framework, with forms now available for dispensaries, manufacturers, distributors, and testing labs. This unlocks federal protections and tax benefits for compliant state-licensed medical operations.
Practical angle: This is the new compliance frontier for anyone in (or reviewing) the regulated space.
4. Ongoing Ripple Effects of Trump-Era Rescheduling
The administration’s April order moving medical marijuana to Schedule III continues driving headlines, with IRS guidance expected on tax implications and expanded research access. White House officials still emphasize cannabis remains federally illegal outside regulated channels.
Big picture: Potential for boosted research, investment, and medical legitimacy — but recreational remains in limbo, creating a two-tier market.
5. State-Level Moves & Broader Trends
- Georgia significantly expanded its medical cannabis program.
- Congress is targeting unregulated intoxicating hemp/cannabinoid products.
- Earnings reports and market forecasts show cautious optimism for 2026 growth amid consolidation.
For stoner lifestyle readers: These shifts directly affect product availability, pricing, innovation, and the culture around hemp vs. regulated cannabis.
These stories dominate today’s cycle because they blend federal drama, business survival, and real-world impacts — perfect for cultivation insights, strain reviews, and unfiltered industry coverage at theStonerReview.com.
Want full articles, X threads, deeper cultivation angles, or custom visuals for any of these? Just say the word. What’s hitting hardest with your audience right now? Stay informed and stay lifted.
